Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Monogram Orthopaedics Inc. Common Stock (MGRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MGRM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.06% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 103.75M USD | Price to earnings Ratio - | 1Y Target Price 5.7 |
Price to earnings Ratio - | 1Y Target Price 5.7 | ||
Volume (30-day avg) 1295770 | Beta - | 52 Weeks Range 1.82 - 4.90 | Updated Date 04/2/2025 |
52 Weeks Range 1.82 - 4.90 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Earnings Date
Report Date 2025-03-13 | When - | Estimate -0.11 | Actual -0.08 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -55.72% | Return on Equity (TTM) -117.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 88460965 | Price to Sales(TTM) 243.53 |
Enterprise Value 88460965 | Price to Sales(TTM) 243.53 | ||
Enterprise Value to Revenue 230.43 | Enterprise Value to EBITDA -5.1 | Shares Outstanding 35289400 | Shares Floating 25687186 |
Shares Outstanding 35289400 | Shares Floating 25687186 | ||
Percent Insiders 34.09 | Percent Institutions 4.21 |
Analyst Ratings
Rating 4 | Target Price 5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Monogram Orthopaedics Inc. Common Stock
Company Overview
History and Background
Monogram Orthopaedics Inc. was founded in 2016 and is focused on developing personalized orthopedic implants using robotic surgical technology. It went public via IPO in 2023.
Core Business Areas
- Robotics and Implants: Development and commercialization of a robotic surgical system for personalized total hip arthroplasty (THA) and total knee arthroplasty (TKA). They create patient-specific implants tailored to individual anatomy.
Leadership and Structure
The leadership team includes Benjamin Sexson (CEO). The company operates with a structure focused on engineering, research and development, and commercialization of its robotic surgical platform.
Top Products and Market Share
Key Offerings
- mBu00f4s System: A robotic surgical system designed for precise placement of personalized hip and knee implants. The market share is still developing but expected to increase through marketing and sales. Major competitors include Stryker, Zimmer Biomet, and Smith & Nephew.
- Personalized Implants: Patient-specific hip and knee implants designed to match individual anatomy based on CT scans. These implants will work with the mBu00f4s System. Competitors include Stryker, Zimmer Biomet, and Smith & Nephew.
Market Dynamics
Industry Overview
The orthopedic implant market is large and growing, driven by an aging population and increasing rates of joint replacement surgeries. The robotic surgery market is also growing as hospitals look to improve precision and outcomes.
Positioning
Monogram Orthopaedics is positioned as a disruptor in the orthopedic implant market, offering personalized implants and robotic assistance. They aim to improve surgical precision and patient outcomes.
Total Addressable Market (TAM)
The total addressable market for hip and knee replacements is estimated to be worth billions of dollars annually. Monogram Orthopaedics is positioned to capture a share of this market with its personalized implants and robotic technology.
Upturn SWOT Analysis
Strengths
- Proprietary robotic surgical technology
- Personalized implant design capabilities
- Potential for improved surgical outcomes
- Strong intellectual property portfolio
Weaknesses
- Limited commercialization experience
- High research and development costs
- Reliance on regulatory approvals
- Limited brand recognition
Opportunities
- Expanding into other orthopedic procedures
- Partnerships with hospitals and surgeons
- Increased adoption of robotic surgery
- Growing demand for personalized implants
Threats
- Competition from established orthopedic companies
- Technological advancements by competitors
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- STRY (Stryker Corporation)
- ZBH (Zimmer Biomet Holdings Inc)
- SNY (Sanofi) - parent company of Sanofi-Aventis, which includes DePuy Synthes
Competitive Landscape
Monogram Orthopaedics faces stiff competition from established players in the orthopedic implant market. They differentiate themselves through personalized implants and robotic assistance, but face challenges in terms of brand recognition and commercialization.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: N/A, pre-commercialization.
Future Projections: Future growth is dependent on regulatory approvals, commercialization of their robotic surgical system, and adoption by surgeons and hospitals.
Recent Initiatives: Focused on securing regulatory approvals for their mBu00f4s System and conducting clinical trials to demonstrate its safety and efficacy.
Summary
Monogram Orthopaedics is an early-stage company with promising technology in the robotic orthopedic surgery space. Their personalized implant approach differentiates them. However, they face significant hurdles, including regulatory approvals, commercialization, and competition from larger companies. The future success depends on their ability to execute their commercialization strategy and achieve widespread adoption of their technology.
Similar Companies
SNY
Sanofi ADR
SNY
Sanofi ADR
ZBH
Zimmer Biomet Holdings Inc
ZBH
Zimmer Biomet Holdings Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share and competitive landscape are approximate estimates based on available information and may vary. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monogram Orthopaedics Inc. Common Stock
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2023-05-18 | Chairman of the Board, President & CEO Mr. Benjamin Sexson C.F.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 27 | |
Full time employees 27 | |||
Monogram Technologies Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.